R1 RCM Inc. (NASDAQ:RCM) Receives $15.41 Consensus Target Price from Analysts

Shares of R1 RCM Inc. (NASDAQ:RCM - Get Free Report) have earned an average rating of "Hold" from the eighteen brokerages that are currently covering the stock, MarketBeat reports. Thirteen equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $15.41.

Several brokerages recently weighed in on RCM. Stephens lowered R1 RCM from an "overweight" rating to an "equal weight" rating in a report on Thursday, August 1st. Leerink Partnrs lowered shares of R1 RCM from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 1st. Cantor Fitzgerald restated a "neutral" rating and set a $14.30 price target on shares of R1 RCM in a research note on Friday, October 4th. Morgan Stanley lowered shares of R1 RCM from an "overweight" rating to an "equal weight" rating in a research note on Thursday, August 8th. Finally, Leerink Partners downgraded R1 RCM from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $17.00 to $14.30 in a research report on Thursday, August 1st.

R1 RCM Price Performance

RCM opened at $14.31 on Thursday. R1 RCM has a fifty-two week low of $8.87 and a fifty-two week high of $15.12. The firm has a 50-day moving average of $14.22 and a 200 day moving average of $13.44. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.79 and a current ratio of 1.79. The firm has a market cap of $6.04 billion, a P/E ratio of -95.40 and a beta of 0.84.

R1 RCM (NASDAQ:RCM - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The healthcare provider reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04). R1 RCM had a negative net margin of 2.48% and a negative return on equity of 2.18%. The firm had revenue of $656.80 million during the quarter, compared to analysts' expectations of $640.93 million. The company's revenue for the quarter was up 14.7% compared to the same quarter last year. On average, research analysts expect that R1 RCM will post -0.38 EPS for the current year.

Institutional Trading of R1 RCM

Hedge funds have recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new stake in R1 RCM during the first quarter valued at about $27,000. GAMMA Investing LLC lifted its stake in shares of R1 RCM by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 2,597 shares of the healthcare provider's stock valued at $37,000 after acquiring an additional 759 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in R1 RCM by 589.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,122 shares of the healthcare provider's stock valued at $44,000 after acquiring an additional 2,669 shares during the period. ANTIPODES PARTNERS Ltd bought a new position in R1 RCM during the 2nd quarter worth approximately $86,000. Finally, Values First Advisors Inc. purchased a new position in R1 RCM in the 3rd quarter worth approximately $88,000. Institutional investors own 61.10% of the company's stock.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.